Life Sciences

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

27 Jan 2020  |  Global  |  Market Research

Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

Infographics

×

Key Issues Addressed

The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

21 Dec 2016  |  Africa  |  Market Research

African Pharmaceuticals Market, Forecast to 2020

Assessing Market Potential with a Focus on Kenya and Nigeria

Infographics

×

The pharmaceuticals market in Africa is expected to reach a business opportunity of $45 billion in 2020, propelled by a convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic lifestyle diseases. The tropical climate of Africa makes the continent the largest re...

Readers of Lab Manager Magazine were invited to participate in an online survey in July 2016. To qualify for survey participation, readers had to play a role in their laboratory’s purchasing process, be familiar with their laboratory’s product budgets, and represent a laboratory that either uses or plans to use products in 1 or more of the 7 sp...

Given the ever-increasing cost of care, healthcare delivery is moving towards decentralisation. Service delivery from health settings such as mobile clinics, rapid retail clinics, and home settings demands the use of new-age clinic laboratory diagnostics. Effective delivery of healthcare services has created a business and technology convergence be...

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...

Given the ever increasing cost of care, healthcare delivery is moving towards decentralisation. Service delivery from healthcare settings such as mobile clinics, rapid retail clinics, and home settings demands the use of new-age clinical laboratory diagnostics. The effective delivery of healthcare services has created a business and technology conv...

The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...